Baseline characteristics of the AML cohort
| Variable . | Number . |
|---|---|
| Patients included | 88 |
| Age, mean (range), y | 43.6 (18-74) |
| Sex (%) | |
| Male | 50 |
| Female | 50 |
| AML type (%) | |
| Acute promyelocytic leukemia | 27 |
| AML with mutated NPM1 | 15 |
| AML with RUNX1-RUNXT1 | 9 |
| AML with CBFB-MYH11 | 5 |
| AML with biallelic mutation of CEBPA | 2 |
| Other AML with recurrent genetic abnormalities | 2 |
| AML not otherwise specified | 40 |
| Non-APL AML risk stratification (ELN 2017, %) | |
| Favorable | 34 |
| Intermediate | 36 |
| Adverse | 30 |
| APL risk stratification (GIMEMA/PETHEMA 2000, %) | |
| Favorable | 4 |
| Intermediate | 15 |
| Adverse | 81 |
| Variable . | Number . |
|---|---|
| Patients included | 88 |
| Age, mean (range), y | 43.6 (18-74) |
| Sex (%) | |
| Male | 50 |
| Female | 50 |
| AML type (%) | |
| Acute promyelocytic leukemia | 27 |
| AML with mutated NPM1 | 15 |
| AML with RUNX1-RUNXT1 | 9 |
| AML with CBFB-MYH11 | 5 |
| AML with biallelic mutation of CEBPA | 2 |
| Other AML with recurrent genetic abnormalities | 2 |
| AML not otherwise specified | 40 |
| Non-APL AML risk stratification (ELN 2017, %) | |
| Favorable | 34 |
| Intermediate | 36 |
| Adverse | 30 |
| APL risk stratification (GIMEMA/PETHEMA 2000, %) | |
| Favorable | 4 |
| Intermediate | 15 |
| Adverse | 81 |
ELN, European LeukemiaNet; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; PETHEMA, Programa de Estudio y Tratamiento de las Hemopatías Malignas.